A Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Study on Specific-Population to Evaluate the Safety and Efficacy of Therapeutic Double-plasmid HBV DNA Vaccine in HBeAg-positive Patients With Chronic Hepatitis B

NCT01189656 Phase 2 UNKNOWN

To preliminarily evaluate the efficiency and safety of therapeutic double- plasmid HBV DNA vaccine on HBeAg-positive, chronic hepatitis B patients, and provide evidence for the next dosing regimen.

Details

Lead sponsor	The 458 Hospital of Chinese PLA
Phase	Phase 2
Status	UNKNOWN
Enrolment	33
Start date	2009-01
Completion	2010-12

Conditions

• Chronic Hepatitis B Patients With HBeAg-positive

Interventions

• HBV DNA Vaccine

Primary outcomes

• The change of HBV DNA load at Week 72 — 72 weeks

Countries

China